A practical reference on trans-3-hexenoyl: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-08 and is reviewed periodically as new material appears.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Argon may be used as the inert gas within Schlenk lines and gloveboxes. Argon is preferred to less expensive nitrogen in cases where nitrogen may react with the reagents or apparatus. Argon may be used as the carrier gas in gas chromatography and in electrospray ionization mass spectrometry; it is the gas of choice for the plasma used in ICP spectroscopy. Argon is preferred for the sputter coating of specimens for scanning electron microscopy. Argon gas is also commonly used for sputter deposition of thin films as in microelectronics and for wafer cleaning in microfabrication.
== Adverse effects == The most common adverse effect of metformin is gastrointestinal irritation, including diarrhea, cramps, nausea, vomiting, and increased flatulence. Metformin is more commonly associated with gastrointestinal adverse effects than most other antidiabetic medications. The most serious potential adverse effect of metformin is lactic acidosis; this complication is rare, and seems to be related to impaired liver or kidney function. Metformin is not approved for use in those with severe kidney disease, but may still be used at lower doses in those with kidney problems.
After completing her PhD, Dayhoff studied electrochemistry under Duncan A. MacInnes at the Rockefeller Institute from 1948 to 1951. In 1952, she moved to Maryland with her family and later received research fellowships from the University of Maryland (1957–1959), working on a model of chemical bonding with Ellis Lippincott. At Maryland, she gained her first exposure to a new high-speed computer, the IBM model 7094. After this ended, she joined the National Biomedical Research Foundation in 1960 as associate director (a position she held for 21 years). At the NBRF, she began to work with Robert Ledley, a dentist who had obtained a degree in physics and become interested in the possibilities of applying computational resources to biomedical problems. He had authored one of the earliest studies of biomedical computation, "Report on the Use of Computer in Biology and Medicine." With their combined expertise, they published a paper in 1962 entitled "COMPROTEIN: A computer program to aid primary protein structure determination" that described a "completed computer program for the IBM 7090" that aimed to convert peptide digests to protein chain data. They actually began this work in 1958, but were not able to start programming until late 1960.
=== Discovery of anti-TB activity === Soon, multiple laboratories discovered anti-TB activity of isoniazid. This led three pharmaceutical companies to unsuccessfully attempt to patent the drug at the same time, the most prominent one being Roche in January 1951, which launched its version, Rimifon, in 1952. Additionally, Soviet physicians A. Kachugin and Bella Keyfman independently discovered this activity in 1949, but neither published their findings in a peer-reviewed article nor applied for an inventor's certificate. The drug was first tested at Many Farms, a Navajo community in Arizona, due to the Navajo reservation's tuberculosis problem and because the population had not previously been treated with streptomycin, the main tuberculosis treatment at the time. The research was led by Walsh McDermott, an infectious disease researcher with an interest in public health, who had previously taken isoniazid to treat his own tuberculosis. Isoniazid and a related drug, iproniazid, were among the first drugs to be referred to as antidepressants. Psychiatric use stopped in 1961 following reports of hepatotoxicity. Use against tuberculosis continued, as isoniazid's effectiveness against the disease outweighs its risks.
== In aggregates == Generally, an aggregate has four different moisture conditions. They are Oven-dry (OD), Air-dry (AD), Saturated surface dry (SSD) and damp (or wet). Oven-dry and Saturated surface dry can be achieved by experiments in laboratories, while Air-dry and damp (or wet) are aggregates' common conditions in nature.
Sources: en.wikipedia.org
Permission to examine, analyze, verify, and reproduce any records and reports that are important to evaluation of a clinical trial. Any party (e.g., domestic and foreign regulatory authorities, sponsors, monitors, and auditors) with direct access should take all reasonable precautions within the constraints of the applicable regulatory requirement(s) to maintain the confidentiality of subjects' identities and sponsor's proprietary information. (ICH E6) Documentation
Rose controlled the family's finances, with Fred giving her his pay packets. The room Rose used for prostitution was known throughout the household as "Mandy's Room" (Mandy being the working name Rose used when she was with her clients) and had several hidden peepholes allowing Fred—a longtime voyeur—to watch her activities. Fred also installed a baby monitor in the room, allowing him to listen from elsewhere in the house. The room included a private bar, and a red light outside the door warned when Rose was not to be disturbed. Rose carried the sole key to this room around her neck, and Fred installed a separate doorbell to the household which her clients were instructed to ring whenever they visited. Much of the money earned from Rose's prostitution was spent on home improvements. By 1977, Rose's father Bill had come to tolerate his daughter's marriage, and to develop a grudging respect for Fred. Together, he and Fred opened a café they named The Green Lantern, which was soon insolvent. When Bill discovered Rose's prostitution, he would also visit Cromwell Street to have sex with his daughter. By 1983, Rose had given birth to eight children, at least three of whom had been conceived by clients. Fred willingly accepted these children as his own, and falsely informed them the reason their skin was darker than that of their siblings was because his great-grandmother was a black woman.
== Treatment == Stopping high vitamin A intake is the standard treatment. Most people fully recover. Phosphatidylcholine (in the form of PPC or DLPC), the substrate for lecithin retinol acyltransferase, which converts retinol into retinyl esters (the storage forms of vitamin A). Vitamin E may alleviate hypervitaminosis A. Liver transplantation may be a valid option if no improvement occurs. If liver damage has progressed into fibrosis, synthesizing capacity is compromised and supplementation can replenish PC. However, recovery is dependent on removing the causative agent: halting high vitamin A intake.
beta bend Also β-bend, beta turn or β-turn. A short segment of a polypeptide chain in which the main direction of the chain changes, i.e. a bend or turn in an otherwise linear polymeric chain. The bend is facilitated by a span of four consecutive amino acid residues where the carboxyl group of the first residue participates in hydrogen bonding with the amino group of the fourth residue.
Sources: en.wikipedia.org
The Bryant Park Restoration Corporation was founded in 1980 by Dan Biederman, along with Andrew Heiskell, chairman of Time Inc. and the New York Public Library. The BPRC immediately brought significant changes to remake the park into a place that people wanted to visit, and instituted a rigorous program to clean the park, remove graffiti, and repair physical damage. The BPRC also created a private security staff to confront unlawful behavior. In addition, the BPRC started an outdoor concert series in the summers. By 1982, arrests had decreased significantly compared to two years prior. Another agency—the Bryant Park Management Corporation, composed of several nearby businesses—was tasked with maintaining the park, spending $525,000 per year to do so. NYC Parks spent an additional $250,000 a year on maintenance, the same amount as when the city had sole control over the park's management. In 1983, HBO's president, Frank Biondi, gave Heiskell a $100,000 check just before the company moved into new headquarters at 1100 Avenue of the Americas, adjacent to the park. At the time, that was the largest donation toward Bryant Park by a private corporation.
=== Bu === John Buchanan (1917–2007). American biochemist at MIT, best known for his research on the biosynthesis of purines. Member Natl. Acad. Sci. USA. Eduard Buchner (1860–1917). German chemist and physiologist at LMU Munich, who overthrew the doctrine of vitalism by showing that cell-free yeast extract could catalyse fermentation, a discovery described by Arthur Kornberg as the beginning of biochemistry. 1907 Nobel Prize in Chemistry. Dean Burk (1904–1988). American biochemist at the Fixed Nitrogen Research Laboratory, co-discoverer of biotin. He is credited (with Hans Lineweaver) with introducing the double-reciprocal plot in kinetics. He became a vociferous opponent of water fluoridation. Robert H. Burris (1914–2010). American biochemist at the University of Wisconsin–Madison, expert on nitrogen fixation. Member Natl. Acad. Sci. USA. Stephen Busby (DPhil 1975) FRS, biochemist at the University of Birmingham. Carlos Bustamante (b. 1951). Peruvian-American biophysicist at UC Berkeley. Known for single-molecule studies, including the use of optical tweezers for measuring the forces that maintain biological structures. Member Natl. Acad. Sci. USA.
=== Examples of intraarticular fractures === Bennett's Fracture intraarticular fracture of the base of the first metacarpal Rolando Fracture comminuted intraarticular fracture of the base of the first metacarpal Calcaneal Fracture fracture of the calcaneus that may extend into the subtalar joint Tibial Plateau Fracture fracture of the proximal portion of the tibia that may extend into the knee joint Pilon Fracture fracture of the distal articular surface of the tibia Distal Radius Fracture fracture of the distal portion of the radius that may extend into the wrist joint Olecranon Fracture fracture of the olecranon process of the ulna at the elbow Femoral Head Fracture fracture of the head of the femur that may extend into the hip joint Some of these fractures such as a Bennett's or Rolando fracture are coined based on their intraarticular involvement, while others such as femoral head fractures, tibial plateau fractures, and distal radius fractures may or may not extend into the joint.
In 2019, the FDA and EMA approved givosiran for the treatment of adults with acute hepatic porphyria (AHP). The FDA also granted givosiran a breakthrough therapy designation, priority review designation, and orphan drug designation for the treatment of acute hepatic porphyria (AHP) in November 2019. By 2020, givosiran received EMA approval. Givosiran is an siRNA that breaks down aminolevulinic acid synthase 1 (ALAS1) mRNA in the liver. Breaking down ALAS1 mRNA prevents toxins (responsible for neurovisceral attacks and AHP disease) such as aminolevulinic acid (ALA) and porphobilinogen (PBG) from accumulating. To facilitate entry into the cytoplasm, givosiran uses GalNAc ligands and enters into liver cells. The medication is administered subcutaneously by a healthcare professional with dosing based on body weight. Warnings and precautions include risk of anaphylactic reactions, hepatic toxicity, renal toxicity and injection site reactions. Lumasiran was approved as a siRNA-based medication in 2020 for use in both the European Union and the United States. This medication is used for the treatment of primary hyperoxaluria type 1 (PH1) in pediatric and adult populations. The drug is designed to reduce hepatic oxalate production and urinary oxalate levels through RNAi by targeting hydroxyacid oxidase 1 (HAO1) mRNA for breakdown. Lowering HAO1 enzyme levels reduces the oxidation of glycolate to glyoxylate (which is a substrate for oxalate). Lumasiran is administered subcutaneously by a healthcare professional with dosing based on body weight.
== External links == Histology image: 42_04 at the University of Oklahoma Health Sciences Center Histology image: 14302loa – Histology Learning System at Boston University Histology at KUMC endo-/endo10 Anatomy Atlases – Microscopic Anatomy, plate 15.287
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.